Randomized Controlled Trial of Adalimumab in Patients With Nonpsoriatic Peripheral Spondyloarthritis

@inproceedings{Mease2015RandomizedCT,
  title={Randomized Controlled Trial of Adalimumab in Patients With Nonpsoriatic Peripheral Spondyloarthritis},
  author={Philip J Mease and Joachim Sieper and Filip Van den Bosch and Proton Rahman and P. M. Karunaratne and Aileen L. Pangan},
  booktitle={Arthritis & rheumatology},
  year={2015}
}
OBJECTIVE To evaluate the efficacy and safety of adalimumab in patients with active nonpsoriatic peripheral spondyloarthritis (SpA). METHODS ABILITY-2 is an ongoing phase III, multicenter study of adalimumab treatment. Eligible patients age ≥18 years fulfilled the Assessment of SpondyloArthritis international Society (ASAS) classification criteria for peripheral SpA, did not have a prior diagnosis of psoriasis, psoriatic arthritis (PsA), or ankylosing spondylitis (AS), and had an inadequate… CONTINUE READING
BETA

Citations

Publications citing this paper.

References

Publications referenced by this paper.
SHOWING 1-10 OF 29 REFERENCES

Efficacy and safety of adalimumab for the treatment of peripheral arthritis in spondyloarthritis patients without ankylosing spondylitis or psoriatic arthritis

  • JE Paramarta, L De Rycke, TF Heijda, CA Ambarus, K Vos, HJ Dinant
  • Ann Rheum Dis ;72:1793–9
  • 2013
Highly Influential
4 Excerpts

Similar Papers

Loading similar papers…